Rare disease pipelines only accelerate through early FDA alignment and breakthrough designations.
Developers of rare and orphan therapies compress clinical timelines and bypass regulatory hurdles by securing early FDA alignment and breakthrough designations.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Securing early Breakthrough Therapy Designation from the FDA helps compress research timelines for developers seeking to fast-track novel rare genetic disease platforms.
Belite Bio accelerated its rare retinal drug submission timeline by executing a rolling pathway secured under the FDA’s Breakthrough designation.
Alterity secures orphan and fast track status to align with the FDA early on Phase 3 design, bypassing regulatory bottlenecks.
Aligning early with the FDA regarding trial design helped clear a path to traditional approval for this rare genetic disease drug.
Early FDA alignment and breakthrough status permitted a rare disease gene therapy to secure a fast route to marketing submission.
uniQure successfully bypassed standard clinical phases by aligning early with the FDA to use Phase I/II study results for its BLA submission.
Acceptance of the BLA under accelerated approval accelerates the commercialization timeline for a candidate targeting a rare kidney disease.